Prognostic value of neutrophil-to-lymphocyte, platelet-to-lymphocyte and lymphocyte-to-monocyte ratio ratios in patients operated on due to non-small cell lung cancer

Abstract

Background: The aim of the study was to determine a prognostic value of the neutrophil to lymphocyte ratio (NLR), the platelet to lymphocyte ratio (PLR) and the lymphocyte to monocyte ratio (LMR) ratios for survival of patients, operated on due to non-small cell lung cancer (NSCLC). Methods: The study was conducted on 532 patients, operated on due to NSCLC, in stages IA-IIIA. A total of 174 females and 358 males, aged 36-84 years (the mean age: 63.6 years) were included in the study. The following factors were subject to a statistical analysis, conducted for determination of potential prognostic values of NLR, PLR and LMR ratios: age, sex, nicotinism, the number of leukocytes, neutrophils, monocytes, platelets, histopathological diagnosis, T category, N category, the Charlson comorbidity index (CCI), kind of surgery, patient survival. Results: The single-factor analysis revealed a relationship between NLR, PLR and LMR values, CCI values, the number of monocytes and the length of survival. The multi-factor analysis confirmed that for patients with expected 2-year survival, PLR above 138 (P=0.0008) is another negative prognostic factor, apart from the stage of the neoplastic disease and CCI above 4. For 5-year survival, such a relationship was not observed. Conclusions: The PLR ratio is an independent and significant prognostic factor for expected, over 2-year survival of patients operated on due to NSCLC.

Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients

“…Pretreatment NLR is associated with the clinical outcomes of several therapeutic interventions in NSCLC patients, such as the response to platinum-based first-line chemotherapy in metastatic NSCLC patients, and the prognosis in operable NSCLC patients 27,28 . Moreover, inflammatory indices, including NLR, PLR, and LMR, are potential prognostic markers for lung cancer patients [29][30][31][32] . Our multivariate analysis demonstrated that high baseline NLR is an independent factor associated with poor PFS and OS.…”

Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti–PD-1 Therapy

“…As such, inflammatory factors can potentially serve as biomarkers for predicting tumor recurrence and prognosis. The neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and platelet-to-lymphocyte ratio (PLR) are prognostic biomarkers ( Chen et al, 2019 ; Imamura et al, 2019 ; Łochowski et al, 2019 ; Yang et al, 2019 ) that have been used to predict response to anti–PD-1 therapy in non-small cell lung cancer (NSCLC), renal cancer, and ovarian cancer, among other malignancies ( Baert et al, 2018 ; Bilen et al, 2018 ; Cao et al, 2018 ; Bartlett et al, 2020 ). In the present study, we analyzed the correlation between NLR, MLR, and PLR and ORR, disease control rate (DCR), and progression-free survival (PFS) as primary endpoints and overall survival (OS) and immune-related adverse events (irAEs) as secondary endpoints in patients with advanced GC and CRC receiving anti–PD-1 therapy in order to determine whether these inflammatory markers have prognostic value in these cancer types.…”

Prognostic effect of preoperative red cell distribution width on the survival of patients who have undergone surgery for non‑small cell lung cancer

“…One possible explanation for the differences in survival between patients with high and low RDW may be variations in the severity of cachexia. Thus far, inflammation-based prognostic systems, such as neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and Glasgow prognostic score (GPS), have been reported in the field of clinical oncology (31)(32)(33). The former two are based on two cellular components, whereas the latter is based on two protein components.…”